SunTrust Upgrades Sarepta Therapeutic (SRPT) to Neutral
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
SunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Reduce to Neutral with a price target of $48.00 (from $4.00).
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
- Sarepta Therapeutics (SRPT) Exondys 51 requires "review of drug and site of care required" at Aetna
- SunTrust Says Interactive Brokers (IBKR) Had "Noisy Quarter", Cuts Estimates & PT
Create E-mail Alert Related CategoriesAnalyst PT Change, Upgrades
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!